BERKELEY HEIGHTS, NJ, October 10, 2000
- Genta Incorporated (Nasdaq:
GNTA
) today announced the appointment of seven lead clinical cancer
specialists to its Scientific Advisory Board.
"With this team, Genta has assembled individuals whom we regard
as world leaders in oncology", said Dr. Raymond P. Warrell, Jr.,
Genta"s President and Chief Executive Officer, who also commented:
"Each member is internationally recognized for his/her expertise in
specific scientific areas that compliment the Company"s ongoing
initiatives. Each has chaired major research programs at the
nation"s leading medical centers. As a group, they bring enormous
expertise in clinical oncology, as well as experimental
therapeutics research with small molecules, proteins and antisense.
The members also have had extensive interactions with their
colleagues at FDA. The advice and insights of this group will be
enormously useful to Genta as we conclude our initial tier of
registration studies with Genasense
TM
, develop our pipeline of compounds, and continue our regulatory
dialog with FDA." (Biographies of individual members follow.)
Daniel D. Von Hoff, MD
, Chairman of Genta"s Scientific Advisory Board, is Professor of
Medicine and Pharmacology and Director of the Cancer Center at the
University of Arizona. He is the immediate past President of the
American Association for Cancer Research, which is the country"s
most prestigious scientific organization in this field. Previously,
Dr. Von Hoff was Founding Director of the Institute for Drug
Development at the Cancer Therapy and Research Center in San
Antonio, and Professor of Medicine at the University of Texas-San
Antonio. In these positions, he participated in the early clinical
investigations of most of the new agents that have been approved
for cancer treatment in the United States over the past 2 decades.
Among numerous awards, he has received the Frederick S. Philips
Lectureship from Memorial Sloan-Kettering Cancer Center, the Michel
Clavel Lectureship from the European Organization for Research and
Treatment of Cancer (EORTC), and the Bagshawe Lectureship from the
British Association for Cancer Research. He has been an editor of
the journal Investigational New Drugs, associate editor of Cancer
Research and Clinical Cancer Research, and has served on the
editorial boards of the American Journal of Medicine,Anticancer
Drugs, Oncology, Annals of Oncology, and 9 other scientific
journals. He is a Fellow of the American College of Physicians, and
has been a member of the Board of Directors of the American Society
of Clinical Oncology (ASCO) and AACR, as well as a member of FDA"s
Oncology Drug Advisory Committee (ODAC). He has published more than
450 papers, 120 book chapters, 750 abstracts, and several patents,
primarily related to studies of new anticancer treatments. Dr. Von
Hoff has also served as a key scientific advisor to a number of
pharmaceutical and biotechnology companies.
Janice Gabrilove, MD
is the James F. Holland Professor and Chief, Division of Medical
Oncology, and Deputy Director for Clinical Affairs, Derald H.
Ruttenberg Cancer Center, at the Mount Sinai Medical Center, New
York, NY. Previously, she was Associate Member at Memorial
Sloan-Kettering Cancer Center and Associate Professor of Medicine
at Cornell University. Dr. Gabrilove received her MD from Mount
Sinai, served her medical internship and residency at Columbia
Presbyterian Hospital, and completed her hematology/oncology
fellowship at Memorial Sloan-Kettering. She is on several editorial
boards of scientific journals, including Blood, Leukemia and
Clinical Cancer Research. She has served as a member of the FDA
Advisory Committee on Cytokines and Biologics and as a consultant
to the FDA Center for Biological Evaluation and Research (CBER).
Dr. Gabrilove holds or has filed a number of patents and patent
applications, including seminal patents related to granulocyte
colony stimulating factor (G-CSF), and she is especially recognized
for her expertise in hematologic oncology.
Michael Grever, MD
is the Charles A. Doan Chairman of Medicine at Ohio State
University School of Medicine. He is also Professor of Medicine and
Program Leader for Experimental Therapeutics at Ohio State"s James
Cancer Center. From 1994 to 1999, he was Director of the
Hematologic Malignancies Section and Professor of Oncology at Johns
Hopkins University School of Medicine. Previously, he held various
positions at the U.S. National Cancer Institute, including Deputy
Director of the Division of Cancer Treatment (DCT), Chair of the
DCT Operating Committee for Cancer Drug Development, and Associate
Director, Developmental Therapeutics. Among other positions, he has
been Leukemia Committee Chair for the Southwest Oncology Group
(SWOG), Leukemia Core Committee member of the Eastern Cooperative
Oncology Group (ECOG), member of the FDA-NCI Working Group for Drug
Development, and Coordinator of the FDA-NCI Blood Level Working
Group. He received his BS and MD from the University of Pittsburgh,
where he also completed his internship and residency in medicine.
He completed his Oncology fellowship at Ohio State. Dr. Grever is
internationally known for his expertise in experimental
therapeutics and hematologic oncology.
Frank G. Haluska, MD, PhD
, is Director of the Melanoma Program at the Massachusetts General
Hospital and Associate Professor of Medicine at Harvard University
Medical School. He received his BA degree from Harvard and his MD
and PhD degrees from the University of Pennsylvania. He was an
intern and resident in medicine at Massachusetts General, fellow in
oncology at the Dana Farber Cancer Center in Boston, Clinical
Fellow in Medicine at Harvard, and a post-doctoral fellow at the
Massachusetts Institute of Technology in Cambridge. Among other
positions, he is Director of the Dana-Farber Harvard Cancer Center
Melanoma and Cutaneous Oncology Program, Co-Director of the Cancer
and Leukemia Group B (CALGB) Melanoma Working Group, and Vice-Chair
of the ASCO Communications Committee. Dr. Haluska is well known for
his expertise regarding novel therapeutics in melanoma.
David Johnson, MD
is the Cornelius A. Craig Chair of Medical and Surgical Oncology
and Director of the Division of Hematology & Oncology at
Vanderbilt University School of Medicine,. He is also Deputy
Director of the Vanderbilt-Ingram Cancer Center. He received his BS
and MS degrees from the University of Kentucky and a MD from the
Medical College of Georgia, where he was Chief Medical Resident. He
completed his oncology training at Vanderbilt. Dr. Johnson is
especially well known for his expertise in lung cancer. Among many
positions, he is currently Chairman of the Lung Committee for ECOG,
member of the ASCO Board of Directors, and a former member of FDA"s
Oncology Drug Advisory Committee.
Howard I. Scher, MD
has been associated with Memorial Sloan-Kettering Cancer Center in
New York for the past 20 years, where he is currently Member,
Attending Physician, and Head of Genitourinary (GU) Oncology in the
Department of Medicine. He is also Professor of Medicine at the
Weill Medical College of Cornell University. He received a BS
degree from Bates College and an MD from New York University School
of Medicine. He was an intern, resident, and chief resident at
Bellevue Hospital, and fellow and chief fellow in oncology at
Memorial Sloan-Kettering. Dr. Scher is internationally known for
his work in GU cancer, with a special focus on prostate cancer.
Cy Aaron Stein, MD, PhD
is Associate Professor of Medicine and Pharmacology at Columbia
University College of Physicians and Surgeons and Associate
Attending Physician at Presbyterian Hospital. He received a BA from
Brown University, an MD from Albert Einstein College of Medicine,
and a PhD from Stanford University. He was an intern and resident
at New York Hospital-Cornell Medical Center, and Clinical Associate
and Senior Staff Fellow at the National Cancer Institute. He is an
editorial board member for Nucleic Acids Research, Bioconjugate
Chemistry, Cancer Gene Therapy, Clinical Prostate Cancer, and
Anticancer Drug Design. He is also the current Co-Editor-in-Chief
of Antisense and Nucleic Acid Drug Development, the leading
specialty journal in antisense. Dr. Stein holds numerous patents
related to experimental therapeutics with antisense and nucleic
acids, and he is a world leader in this research area.
